Kornimate/medical-research-clean huggingface dataset:
ileal interposition with sleeve gastrectomy for control of diabetes

Conditions: Diabetes

Summary: ileal interposition shifts a segment of ileum proximally to achieve maximal meal stimulated glucagon-like peptide-1 secretion and coupled with a limited/complete sleeve gastrectomy (depending on the body mass index), for ghrelin reduction, helps in achieving good glycemic control in type 2 diabetes patients.

laparoscopically, using 6 ports, the ileum is tarnsected at 30 cms proximal to ileo-caecal junction and at 200 cms proximal to ileo-caecal junction;this ileal segment of 170 cms is interposed into proximal jejunum between 20-50 cms distal to ligament of treitz. endo-gia staplers and hand-sown closure was used for the 3 anastomoses. the mesenteric gaps defects were closed with 3/0 prolene sutures. sleeve gastrectomy was done starting from antrum/body upto angle of his with a sizing bougie ranging from size 32--58 fr.

Eligibility criteria:
inclusion criteria: * type 2 diabetes (as defined by american diabetes association criteria)of more than 1 year duration * body mass index 21 - 55 kg/m\^2 * poor glycemic control (hba1c \> 8%) despite maximal use of oral hypoglycemic agents and insulin; or good control(lower hba1c) but requiring progressively higher drug doses. * gives informed consent for the surgery * postmeal c peptide \> 1.0 ng/ml * age 25 - 75 years * stable weight for more than 3 months exclusion criteria: * type 1 diabetes * postmeal c peptide \< 1 ng/ml * pregnancy * significant nephropathy requiring dialysis * coexisting systemic disease * previous gastric or intestinal resection surgery * obesity due to organic illness

Keywords: ileal interposition sleeve gastrectomy type-2 diabetes
workplace-sponsored diet and exercise program to reduce obesity

Conditions: Obesity; Cardiovascular Diseases; Heart Diseases

Summary: this study will evaluate the effectiveness of an environmental worksite intervention to reduce obesity among hospital employees.

background: obesity is a significant public health problem in the united states, prompting policy makers and researchers to call for action against the epidemic. obesity and associated health conditions affect all age groups and both genders, yet disproportionately affect racial and ethnic minorities. health consequences of obesity include high blood pressure, high cholesterol, hyperinsulinemia, type 2 diabetes, heart disease, stroke, gallbladder disease, arthritis, sleep disturbances, breathing problems, and certain types of cancer. hospitals are important worksite environments that employ large numbers of people in diverse job categories from diverse educational and socioeconomic backgrounds. design narrative: the purpose of this study is to promote weight loss among those who are overweight and obese, and prevent weight gain among those of normal weight through an environmental intervention targeted to all employees at six hospitals in central massachusetts. the hospitals will be matched according to size, and within each matched pair randomly assigned to either the intervention or control group. the intervention will promote active living, in which physical activity is incorporated into each participants' daily routine. participants will also follow a healthy diet, characterized by higher intakes of fruits, vegetables, fish, poultry, legumes, and whole grains. participants will consume less high fat foods and refined grains, and reduce their total caloric intake through smaller portion sizes.

Eligibility criteria:
inclusion criteria: * works at least 20 hours per week at a participating hospital * speaks english or spanish exclusion criteria: * works at only one hospital within the participating hospital system
the effects of different music genres on heart rate variability in extremely and very low birth weight newborns

Conditions: Infant Behavior; Infant Conditions; Infant Morbidity

Summary: aim: to investigate the influence of different music genres on heart rate variability (hrv) of preterm infants. neonates undergo a daily randomized music listening program. an electrocardiogram is performed to evaluate hrv parameters in each neonate with and without music exposure.

aim: to investigate the influence of different music genres on heart rate variability (hrv) of preterm infants. hrv has been previously used to evaluate autonomic nervous system fluctuations in heart rate related to maturation in healthy neonates and in neonates with pathological conditions. this parameter has been used to show how music could improve well-being and the development of the autonomic nervous system in infants. in this study, neonates (see also inclusion/exclusion criteria), recruited on the basis of birth order, undergo a daily randomized music listening program (25 minutes, every day, for 3 days) based on different music genres listening (soft pop-rap, pop-rock and classical music). music programs is followed by 1 day of no music monitoring (25 minutes). an electrocardiogram is performed to evaluate hrv parameters in each neonate with and without music exposure.

Eligibility criteria:
inclusion criteria: * gestational age between the 23th and the 32nd week * birth weight \<1500g * appropriate for gestational age, sufficient stability of the vital parameters and absence of active infections and episodes of apnoea during the 72 hours before the test exclusion criteria: * genetic anomalies, chromosomal aberrations, congenital heart malformations, intraventricular haemorrhage (\> grade ii on ultrasound), periventricular leukomalacia * neonates with failed responses to bilateral hearing screening performed by automated auditory brainstem response testing

Keywords: music preterm infants heart rate variability
dissemination and implementation of stroke prevention looking at the care environment

Conditions: Sickle Cell Disease

Summary: the dissemination and implementation of stroke prevention looking at the care environment (displace) study is a multi-center, national, national heart, lung and blood institute (nhlbi)-funded grant to look at the real-world implementation of stroke prevention guidelines (stop protocol) in which transcranial doppler (tcd), a measure of cerebral blood vessel velocity, is used to screen for stroke risk in children ages 2-16 with sickle cell anemia (sca). part 3 of the displace study is an implementation clinical trial designed to test novel implementation strategies with the goal of improving adherence and implementation of stroke screening. 16 of the lowest scoring implementation rates from displace part 1 will participate in displace part 3. all original 28 sites from displace parts 1 and 2 will receive a patient and provider educational intervention including a re-branding of the tcd as "sickle stroke screen" with a new infographic and educational materials. the 16 sites with moving to part 3 will be provided a provider reminder strategy, which is a web based application designed to remind providers of when patients are due for their sickle stroke screen. these 16 sites will be randomized and 8 will be given an additional patient communication strategy. these sites will have a single designed coordinator with whom patients will communicate with about scheduling, rescheduling, and any other questions regarding their sickle stroke screen. upon completion, data will be analyzed to compare those who have had tcd screenings done appropriately and those who did not as well as the overall effect of the multi level interventions on the changes in tcd rates.


Eligibility criteria:
inclusion criteria: * patients with sickle cell anemia (sca) identified at each institution through international classification of diseases 9/10 (icd-9/icd-10) codes and local patient databases. * patients must have been seen by the designated institution (documented in medical record) a minimum of two times in the either inpatient or outpatient setting at the institution between the years of 01/01/2018-12/31/2019. * patients identified will include those currently aged 2-7. thus children born from 2012 and onward. * patients already receiving primary or secondary stroke prevention therapy with crct will be included in registration in web data coordination unit (webdcu) but not included in provider minder as they do not require ongoing tcd/sickle stroke screen based on protocol. exclusion criteria: * patients who do not have sca * patients who were born before 2012 and therefore do not meet age criteria.
loss to follow-up in pdr patients

Conditions: Diabetic Retinopathy

Summary: this study determined the clinical impact and causes of loss to follow-up (ltfu) from the patients' perspective in individuals with proliferative diabetic retinopathy (pdr) who received panretinal photocoagulation (prp) and/or intravitreal injections (ivis) of anti-vascular endothelial growth factor (vegf). this prospective cohort study included 467 patients with pdr who received prp and/or ivis of anti-vegf between may 2013 and june 2018. ltfu was defined as missing any follow-up visit for any interval exceeding 6 months, provided that patients eventually resumed care. main outcome measures include rates and causes of ltfu.


Eligibility criteria:
inclusion criteria: * included treatment-naïve patients who had developed pdr in one eye with a best corrected visual acuity (bcva) ranging from 20/22 to 20/69, as determined by the snellen equivalent. patients were allocated to receive prp, ivis of anti-vegf, or a combination of both procedures. exclusion criteria: 1. patients receiving follow-up ophthalmic care for their pdr with or without interventions at any other medical care provider during the observation period, as declared by the patients at any follow up visit. 2. patients ltfu who did not resume follow-up until the end of the observation period. 3. patients needing ppv at first presentation or having additional retinal pathology. 4) patients receiving their treatment procedure during december 2017 or having vitreous hemorrhage that failed to clear up by june 2018 but still ineligible candidates for ppv.

Keywords: loss to follow-up proliferative diabetic retinopathy diabetic retinopathy panretinal photocoagulation intravitreal injections
three-dimensional (3d) holographic display for ultrasound-guided structural heart disease procedures

Conditions: Structural Cardiac Defects

Summary: this study is intended to evaluate the use of the holographic display of 3d images acquired during ultrasound based cardiac procedures and to assess the clinical use of the holoscope-i, in providing 3d spatial understanding to the clinician performing the procedure. patients scheduled to undergo an elective procedure in the cardiac catheterization laboratory which use 3d echocardiography (echo) as part of the procedure will be enrolled to this study. in addition to the standard of practice imaging using ultrasound, patients anatomical structures will be evaluated using a 3d holographic system. the patients will complete their participation in the study, at the end of the procedure. no follow-up is required and patients will continue their routine medical care following the procedure.


Eligibility criteria:
inclusion criteria: * patients over the age of 18 * patients are scheduled to undergo an elective procedure in the cardiac catheterization laboratory which use 3d echocardiography (echo) as part of the procedure. exclusion criteria: * denial of informed consent * any contraindications to three-dimensional echocardiographic imaging.
computer-based intervention in hiv-positive young adults

Conditions: HIV; Depression

Summary: the purpose of this study is to investigate how working with a computer program may affect mood, feelings, overall health, and markers in blood in young adults with hiv.

depression frequently occurs in young adults with hiv infection. when young adults with hiv experience depression, they are less likely to take their prescribed antiretroviral therapy (art). when hiv occurs simultaneously with depression, individuals are more likely to have indicators in their blood that are linked risk for developing other illnesses in the future. the purpose of this project is to examine the ability of an avatar-based intervention, called esmart-mh, to decrease depressive symptoms in hiv-positive depressed young adults.

Eligibility criteria:
inclusion criteria: * 23-53 years of age * fluent in english * be able to view images and text on a computer screen and hear audio using a headset * have a diagnosis of unipolar depression or have significant depressive symptoms noted in the electronic medical record (emr) or referred to the study by a provider at the grady ponce de leon clinic because of their depressive symptoms * receive care at ponce de leon center and at least 1 scheduled hiv medical appointment in the last 6 months * reside in the atlanta, georgia area * have a valid telephone number and email address * answer all items correctly on consent post-test exclusion criteria: * diagnosis of bipolar depression * deaf, blind or unable to understand spoken english * currently pregnant, history of pregnancy within the last year or plan to become pregnant within the next 4 months * plan to move from the atlanta, georgia area within four months of study enrollment * taking corticosteroids or disease-modifying anti-rheumatic drugs * if on antidepressant medication, taking it for less than 1 month * fail to pass post-consent test after three attempt
gevokizumab with standard of care anti-cancer therapies for metastatic colorectal, gastroesophageal, and renal cancers

Conditions: Colorectal Cancer; Gastroesophageal Cancer; Renal Cell Carcinoma

Summary: this study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma, and the preliminary efficacy of gevokizumab in combination with the soc anti-cancer therapy in subjects with mcrc and mgec.


Eligibility criteria:
inclusion criteria: * metastatic disease not amenable to potentially curative surgery and with available archival tumor tissue or fresh tumor tissue biopsy. * presence of at least 1 measurable lesion assessed by ct and/or mri according to recist 1.1. for cohort a: - first line metastatic colorectal cancer. for cohort b: - second line metastatic colorectal cancer that has progressed on prior chemotherapy administered for metastatic disease and which must include a fluoropyrimidine and oxaliplatin. for cohort c: - second line metastatic gastroesophageal cancer that has progressed on prior line of chemotherapy administered for metastatic disease, and which must include a platinum agent and fluoropyrimidine doublet. for cohort d: - second or third line metastatic renal cell carcinoma with a clear-cell component and has received one or two lines of treatment for metastatic disease that included an anti-angiogenic agent for at least 4 weeks with radiologic progression on that treatment. for subjects starting from part 1a in cohorts a and b: * serum hs-crp at screening ≥ 10 mg/l. * not requiring immediate initiation of anti-cancer therapy per investigator's best judgement. for subjects starting from part 2 in cohort c: - serum hs-crp at screening ≥ 10 mg/l. exclusion criteria: for all cohorts: * currently receiving any of the prohibited medications or has contraindications as outlined in the protocol. * symptomatic brain metastases or brain metastases that require directed therapy (such as focal radiotherapy or surgery). * suspected or proven immunocompromised state, or infections (as defined in the protocol). * conditions that have a high risk of clinically significant bleeding after administration of anti-vegf agents. * clinically significant, uncontrolled or recent (within last 6 months) cardiovascular disease. for cohort d: * concomitant medications, herbal supplements, and/or fruits and their juices that are known as strong inhibitors or inducers of cyp3a4/5, and medications that have a narrow therapeutic window and are predominantly metabolized through cyp3a4/5. * impairment of gi function or gi disease that may significantly alter the absorption of cabozantinib. other protocol-defined inclusion/exclusion criteria may apply

Keywords: colorectal cancer gastroesophageal cancer renal cell carcinoma gevokizumab bevacizumab modified folfox6 folfiri ramucirumab paclitaxel cabozantinib crc gec rcc vpm087
study of the efficacy and safety of intravitreal (ivt) aflibercept for the improvement of moderately severe to severe nonproliferative diabetic retinopathy (npdr)

Conditions: Nonproliferative Diabetic Retinopathy

Summary: the primary objective of the study is to assess the efficacy of intravitreal (ivt) aflibercept compared to sham treatment in the improvement of moderately severe to severe nonproliferative diabetic retinopathy (npdr). the secondary objectives of the study are: * to characterize the safety of ivt aflibercept in patients with moderately severe to severe npdr * to determine if ivt aflibercept will prevent the worsening of diabetic retinopathy and reduce the incidence of dme * to determine the anatomic effects of ivt aflibercept in patients with moderately severe to severe npdr


Eligibility criteria:
key inclusion criteria: 1. men or women ≥18 years of age with type 1 or 2 diabetes mellitus who have moderately severe to severe nonproliferative diabetic retinopathy (npdr) \[(diabetic retinopathy severity scale (drss) levels 47 or 53)\], confirmed by the central reading center, in whom panretinal photocoagulation (prp) can be safely deferred for at least 6 months per the investigator 2. best corrected visual acuity (bcva) early treatment diabetic retinopathy study (etdrs) letter score in the study eye of ≥69 letters (approximate snellen equivalent of 20/40 or better) key exclusion criteria: 1. presence of diabetic macular edema (dme) threatening the center of the macula in the study eye 2. evidence of retinal neovascularization on clinical examination or fluorescein angiography (fa) 3. any prior focal or grid laser photocoagulation or any prior prp in the study eye 4. any prior systemic anti-vascular endothelial growth factor (vegf) treatment or intravitreal (ivt) anti-vegf treatment in the study eye 5. any prior intraocular steroid injection in the study eye 6. current anterior segment neovascularization (asnv), vitreous hemorrhage, or tractional retinal detachment visible at the screening assessments in the study eye note: other inclusion/ exclusion criteria apply
a study of xeloda (capecitabine) in patients with advanced and/or metastatic colorectal cancer

Conditions: Colorectal Cancer

Summary: this study will assess the efficacy and safety of continuous oral xeloda administration in combination with intravenous irinotecan as a first-line treatment in patients with advanced and/or metastatic colorectal cancer. the anticipated time on study treatment is 3-12 months and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * adult patients \>=18 years of age; * locally advanced and/or metastatic colorectal cancer; * \>=1 target lesion. exclusion criteria: * previous treatment with xeloda or irinotecan; * previous systemic therapy for metastatic disease; * progressive disease during previous adjuvant therapy or within 6 months of completion.
trial assessing the effect of preoperative furosemide on intraoperative blood pressure

Conditions: Hypertension; Hypotension; Edema; Congestive Heart Failure

Summary: the purpose of this study is to determine whether continuing or discontinuing furosemide (a diuretic) on the day of elective noncardiac surgery for those who take furosemide on a chronic basis, causes more intraoperative hypotension (low blood pressure) during surgery. our hypothesis is that the usual practice of continuing furosemide on the day of surgery would contribute to more hypotension during surgery than discontinuing furosemide.

a significant proportion of patients who undergo surgery take medications on a chronic basis. little is known about the effects of these medications on the successful conduct of anesthesia and surgery. diuretics like furosemide may contribute to low blood pressure during surgery, an outcome associated with cardiovascular complications. however, many patients are recommended to take their diuretics on the day of surgery. we wished to determine if preoperative administration of furosemide contributes to intraoperative hypotension compared to placebo. comparison: we conducted a randomized, double blind placebo controlled trial to compare the effect of furosemide with that of placebo on intraoperative hypotension using intraoperative blood pressure recordings in patients who take furosemide chronically and were undergoing noncardiac surgery.

Eligibility criteria:
inclusion criteria: * all adults referred to preoperative assessment clinics by surgeons for elective non-cardiac surgery who routinely take furosemide. * participants must also be able to give informed consent exclusion criteria: * less than 18 years of age * have comorbid conditions with which brief periods of hypotension may be particularly harmful such as: 1) pregnancy; 2) baseline hypotension (systolic \<100 mmhg at the preoperative assessment clinic); 3) autonomic dysfunction; 4) severe aortic stenosis. * patients who take furosemide only on an 'as needed basis' rather than 'regularly'. * those patients who take less than 10 mg of furosemide daily * those patients who are undergoing local anesthetic only surgical procedures * patients who are unwilling or unable to give informed consent.

Keywords: anesthesia hypotension furosemide blood pressure peripheral edema diuretic surgery congestive heart failure